Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]

Episode von Medizin - Open Access LMU - Teil 14/22 von Ludwig-Maximilians-Universität München · 1. Januar 2005

Background: Safe, effective and affordable drug combinations against falciparum malaria are urgently needed for the poor populations in malaria endemic countries. Methylene blue (MB) combined with chloroquine (CQ) has been considered as one promising new regimen. Objectives: The primary objective of this study was to evaluate the safety of CQ-MB in African children with uncomplicated falciparum malaria. Secondary objectives were to assess the efficacy and the acceptance of CQ-MB in a rural population of West Africa. Methods: In this hospital-based randomized controlled trial, 226 children ( 6 - 59 months) with uncomplicated falciparum malaria were treated in Burkina Faso. The children were 4: 1 randomized to CQ-MB (n = 181; 25 mg/kg CQ and 12 mg/kg MB over three days) or CQ ( n = 45; 25 mg/kg over three days) respectively. The primary outcome was the incidence of severe haemolysis or other serious adverse events (SAEs). Efficacy outcomes were defined according to the WHO 2003 classification system. Patients were hospitalized for four days and followed up until day 14. Results: No differences in the incidence of SAEs and other adverse events were observed between children treated with CQ-MB ( including 24 cases of G6PD deficiency) compared to children treated with CQ. There was no case of severe haemolysis and also no significant difference in mean haemoglobin between study groups. Treatment failure rates were 53.7% (95% CI [37.4%; 69.3%]) in the CQ group compared to 44.0% ( 95% CI [36.3%; 51.9%]) in the CQ-MB group. Conclusion: MB is safe for the treatment of uncomplicated falciparum malaria, even in G6PD deficient African children. However, the efficacy of the CQ-MB combination has not been sufficient at the MB dose used in this study. Future studies need to assess the efficacy of MB at higher doses and in combination with appropriate partner drugs.

Weitere Episoden von „Medizin - Open Access LMU - Teil 14/22“

• A role for MCP-1/CCR2 in interstitial lung disease in children 1. Januar 2005
• A simple approach for protein name identification: prospects and limits 1. Januar 2005
• An extrahippocampal projection from the dentate gyrus to the olfactory tubercle 1. Januar 2005
• Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease 1. Januar 2005
• Chemokine receptor CCR1: A new target for progressive kidney disease 1. Januar 2005
• Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis 1. Januar 2005
• Concerted upregulation of CLP36 and smooth muscle actin protein expression in human endometrium during decidualization 1. Januar 2005
• Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock 1. Januar 2005
• Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease 1. Januar 2005
• Fluorescence in situ hybridization to chromosomes as a tool to understand human and primate genome evolution 1. Januar 2005
• Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease 1. Januar 2005
• Gene expression profile and synovial microcirculation at early stages of collagen-induced arthritis 1. Januar 2005
• Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease 1. Januar 2005
• Hahnemann's legacy in a new light - A systematic approach to the Organon of Medicine 1. Januar 2005
• 3D Analysis of chromosome architecture: advantages and limitations with SEM 1. Januar 2005

Alle Episoden von Medizin - Open Access LMU - Teil 14/22 · Mehr Bildung-Podcasts